Wall Street analysts expect Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report sales of $59.63 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Halozyme Therapeutics’ earnings. The highest sales estimate is $65.89 million and the lowest is $55.35 million. Halozyme Therapeutics reported sales of $60.23 million in the same quarter last year, which indicates a negative year over year growth rate of 1%. The company is expected to issue its next earnings results on Thursday, February 20th.
On average, analysts expect that Halozyme Therapeutics will report full year sales of $201.96 million for the current year, with estimates ranging from $197.68 million to $208.22 million. For the next fiscal year, analysts expect that the firm will post sales of $203.71 million, with estimates ranging from $190.06 million to $221.44 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Halozyme Therapeutics.
Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.05). Halozyme Therapeutics had a negative net margin of 19.73% and a negative return on equity of 15.76%. The firm had revenue of $46.20 million during the quarter, compared to analysts’ expectations of $54.96 million. During the same period last year, the company earned ($0.19) EPS. The business’s quarterly revenue was up 80.5% on a year-over-year basis.
HALO has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective for the company in a research report on Thursday, November 7th. ValuEngine cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. Barclays raised shares of Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and lowered their price objective for the stock from $17.00 to $16.00 in a research report on Tuesday, November 5th. Finally, BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $20.50.
Shares of NASDAQ:HALO traded up $0.26 during mid-day trading on Friday, reaching $18.98. 1,212,665 shares of the company were exchanged, compared to its average volume of 1,663,413. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.17 and a quick ratio of 2.83. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -33.89 and a beta of 1.89. The firm’s 50-day simple moving average is $17.87 and its 200 day simple moving average is $16.60. Halozyme Therapeutics has a 1 year low of $13.24 and a 1 year high of $19.73.
Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its holdings in Halozyme Therapeutics by 8.0% during the 2nd quarter. BlackRock Inc. now owns 12,625,128 shares of the biopharmaceutical company’s stock worth $216,900,000 after buying an additional 929,980 shares in the last quarter. UBS Asset Management Americas Inc. lifted its holdings in Halozyme Therapeutics by 16.8% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 116,933 shares of the biopharmaceutical company’s stock worth $2,009,000 after buying an additional 16,784 shares in the last quarter. Aperio Group LLC lifted its holdings in Halozyme Therapeutics by 4.4% during the 2nd quarter. Aperio Group LLC now owns 26,756 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 1,120 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $20,404,000. Finally, Morgan Stanley lifted its holdings in Halozyme Therapeutics by 35.5% during the 2nd quarter. Morgan Stanley now owns 370,841 shares of the biopharmaceutical company’s stock worth $6,372,000 after buying an additional 97,144 shares in the last quarter. Institutional investors own 84.98% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Read More: Asset Allocation Models, Which is Right For You?
Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.